Royal Vision 2030 to revitalize the pharmaceutical Industry in Saudi Arabia

In mid-2014, the Kingdom of Saudi Arabia (KSA) faced one of the
most daunting economic development challenges of its modern
history, when crude oil prices collapsed by more than half, our
local correspondent writes.

On ascending the throne in January 2015, King Salman bin
Abdulaziz Al Saud and his son Crown Prince Mohammed bin Salman Al
Saud initiated an ambitious socio- economic reform plan,
Kingdom’s Vision 2030, which was launched on April…

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source